Profluent
Generates custom proteins and gene-editing systems using deep learning models.
What they do
Profluent applies generative AI, trained on massive protein sequence datasets, to design entirely new biomolecules. Biopharma companies and research laboratories use the platform to develop customized proteins and CRISPR-like gene editors optimized for specific therapeutic functions.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein design
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Berkeley, USA
- Region
- North America
- Founded
- 2022
- Total funding
- $44M raised
Notable investors: Spark Capital, Insight Partners, Air Street Capital, AIX Ventures.